Resverlogix Corp. ((TSE:RVX)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Resverlogix Corp. is conducting a Phase II clinical study titled ‘A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone With Background Dapagliflozin in Subjects With Long-COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)’. The study aims to evaluate the efficacy and safety of Apabetalone, an oral drug, in treating long-COVID symptoms in patients with T2DM. This research is significant as it addresses the ongoing health challenges faced by individuals with long-COVID.
The intervention being tested is Apabetalone, a drug that selectively binds to BET proteins to curb the transcription of genes associated with vascular inflammation and other related conditions. It is administered as a 100-mg capsule taken twice daily with meals.
This open-label, single-group study is designed to treat patients, with no masking involved. The primary purpose is to assess treatment efficacy and safety over a 12-week period.
The study began on August 26, 2024, and the latest update was submitted on April 15, 2025. These dates are crucial as they indicate the study’s progression and current status in the recruitment phase.
The update on this study could influence Resverlogix Corp.’s stock performance positively, as successful results may boost investor confidence. The study’s focus on long-COVID, a condition with significant market interest, places Resverlogix in a competitive position within the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.